A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Abstract Background Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal ne...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Maximilian Mastall, Patrick Roth, Andrea Bink, Angela Fischer Maranta, Heinz Läubli, Andreas Felix Hottinger, Thomas Hundsberger, Denis Migliorini, Adrian Ochsenbein, Katharina Seystahl, Lukas Imbach, Tibor Hortobagyi, Leonhard Held, Michael Weller, Hans-Georg Wirsching
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-01-01
Colecção:	BMC Cancer
Assuntos:	Epilepsy Gabapentin Sulfasalazine Memantine Cancer neuroscience
Acesso em linha:	https://doi.org/10.1186/s12885-023-11797-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!